Risk-Reducing Surgery for High-Risk Gene Carriers

For women who carry a mutation in a high-risk breast cancer gene, the prospect of developing breast cancer is not a distant statistical possibility — it is a meaningful and significant lifetime risk that shapes how they think about their health, their future, and their family. Understanding the surgical options available for reducing that risk is an important part of navigating what can be a complex and emotionally demanding situation.

Risk-reducing surgery — also called prophylactic surgery — refers to the surgical removal of healthy breast tissue before cancer develops, with the goal of substantially reducing the lifetime risk of breast cancer. It is the most effective risk-reduction intervention available for high-risk gene carriers, reducing the risk of breast cancer by approximately 95%.

The decision to pursue risk-reducing surgery is one of the most significant a woman can make. It is not right for everyone, and it is never a decision that should be rushed. At Breast & Surgical Oncology at The Poche Centre, our surgeons approach risk-reducing surgery with the time, expertise, and sensitivity it deserves — providing thorough information, honest guidance, and support through every stage of the decision-making process and beyond.

Who Is Risk-Reducing Mastectomy For?

Risk-reducing mastectomy is most commonly considered by women who carry a confirmed pathogenic mutation in a high-risk breast cancer gene. The most well-known are BRCA1 and BRCA2, but other genes including PALB2, CDH1, and PTEN are also associated with significantly elevated lifetime breast cancer risks for which risk-reducing surgery may be appropriate.

BRCA1 carriers have a lifetime breast cancer risk of approximately 50 to 72%. The cancers associated with BRCA1 mutations tend to be high-grade and triple-negative, making them more aggressive and less responsive to hormonal therapies. As chemotherapy is usually needed to treat BRCA1-associated cancers, surgical risk reduction is an important consideration for carriers.

BRCA2 carriers have a lifetime breast cancer risk of approximately 45 to 69%. BRCA2-associated breast cancers are more commonly hormone receptor-positive, meaning hormonal therapy options are available, but the lifetime risk remains very substantially elevated compared to the general population.

PALB2 carriers have an estimated lifetime breast cancer risk of approximately 35 to 60% depending on family history, placing them in a risk category comparable to BRCA2 for whom risk-reducing surgery warrants serious consideration.

CDH1 carriers have an elevated risk of lobular breast cancer alongside a very high risk of diffuse gastric cancer, and bilateral prophylactic mastectomy is recommended as the standard of care for confirmed CDH1 mutation carriers given the challenges of screening for lobular breast cancer.

PTEN mutation carriers (Cowden syndrome) carry a lifetime breast cancer risk of approximately 25 to 50% and may be offered risk-reducing mastectomy depending on family history, personal risk factors, and the outcome of risk-benefit discussion.

Risk-reducing mastectomy may also be considered for women without a confirmed gene mutation but with an extremely strong family history of breast and ovarian cancer, a personal history of DCIS or LCIS in the context of elevated risk, or prior chest radiotherapy in combination with other high-risk features. Eligibility and appropriateness are always assessed on an individual basis.

The Decision-Making Process

The decision to undergo risk-reducing mastectomy is deeply personal and highly individual. Two women with the same BRCA1 mutation may make completely different and equally valid decisions — one choosing surgery, the other choosing intensive surveillance. Neither choice is wrong.

What matters is that the decision is fully informed, carefully considered, made at the right time for the individual, and supported by appropriate specialist input throughout.

Genetic counselling is the essential first step. Before any surgical decision is made, a formal genetic counselling consultation should have taken place, through a familial cancer service or clinical geneticist. This ensures the gene mutation is accurately interpreted, the implications for other family members are understood, and the emotional and practical dimensions of testing and its results have been properly explored.

Timing is personal. There is no universally correct age at which risk-reducing mastectomy should be performed. For BRCA1 and BRCA2 carriers, risk starts to increase meaningfully from the mid-to-late twenties, and current guidelines generally suggest that risk-reducing mastectomy can be considered from age 25 to 35 for BRCA1 carriers and somewhat later for BRCA2. However, decisions about timing should account for family-building plans, fertility and hormonal considerations, emotional readiness, and the patient's own values and priorities.

Surveillance as an alternative. For women who are not ready for or do not wish to pursue surgery, intensive surveillance — annual breast MRI and mammography, regular clinical examination — is a clinically supported alternative that allows ongoing monitoring while the decision is considered at the patient's own pace. Surveillance does not reduce the risk of developing breast cancer, but it maximises the chance of early detection. Our team will advise on the most appropriate surveillance program for your risk level.

Take the time you need. There is no urgency in this decision for most patients. A woman who discovers she carries a BRCA1 mutation at age 30 has time to consider her options carefully, explore reconstruction, speak with other patients, and make a decision that feels right for her life. Our surgeons never pressure patients toward or away from surgery and are equally supportive of patients who choose intensive surveillance as those who choose surgical risk reduction.

Pre-Surgical Workup

Before proceeding with risk-reducing mastectomy, a thorough pre-operative assessment is completed to ensure there is no occult (undetected) breast cancer present at the time of surgery. This typically includes a bilateral breast MRI (the most sensitive screening tool for high-risk women), a digital mammogram, and a clinical breast examination. If any suspicious findings are identified, these are investigated with biopsy before proceeding to risk-reducing surgery.

Screening for concurrent ovarian cancer risk (where BRCA1 or BRCA2 mutation is present) is also discussed, as the question of risk-reducing salpingo-oophorectomy is closely related and often considered in the same planning process. Your surgeon will ensure coordination with the appropriate specialists.

Most women contemplating risk reducing mastectomy will benefit from seeing a psychologist to unpack the many issues surrounding the decision - fear, anxiety, guilt, body image, family, intimacy, recovery, work to name a few. Engaging a psychologist as part of your treating team can is an important aspect of care which we encourage. Our team will organise a referral to the right psychologist with expertise in this area and a Mental Health Care Plan form your GP will enable a rebate from Medicare.

The Operation

Risk-reducing mastectomy involves the surgical removal of all breast tissue from one or both breasts. For women at bilateral risk, as is the case for BRCA1 and BRCA2 carriers, the procedure is typically performed as a bilateral mastectomy (both breasts) in a single operation.

The mastectomy technique used depends on whether reconstruction is planned and the patient's anatomy. The most commonly used approaches in the risk-reducing setting are skin-sparing mastectomy and nipple-sparing mastectomy, both of which preserve the breast skin envelope for reconstruction.

Nipple-sparing mastectomy preserves the entire skin envelope including the nipple and areola, with all breast tissue removed from beneath. Nipple-sparing mastectomy produces the most natural-appearing result after reconstruction and is suitable for the majority of women undergoing risk-reducing surgery, who tend to be younger with less breast ptosis than women undergoing mastectomy for established cancer. Where anatomically feasible, nipple-sparing mastectomy is our preferred approach in the risk-reducing setting.

Skin-sparing mastectomy preserves most of the breast skin but removes the nipple-areola complex. It is used when nipple-sparing is not anatomically appropriate — for example, in women with significant breast ptosis, larger breast size, or where the nipple biopsy raises concern.

The choice of mastectomy technique is always made in the context of your individual anatomy, preferences, and reconstruction plan, and is discussed in detail at your pre-operative consultation.

Reconstruction After Risk-Reducing Mastectomy

Breast reconstruction is performed in the great majority of women undergoing risk-reducing mastectomy, most commonly as immediate reconstruction at the time of the mastectomy. Because risk-reducing mastectomy is a planned, elective procedure performed in healthy women who do not require post-mastectomy radiotherapy, the conditions for immediate reconstruction are generally excellent — and the aesthetic results achievable are among the best in the field of breast reconstruction.

The range of reconstruction options available after risk-reducing mastectomy is the same as after mastectomy for breast cancer, and includes the following.

Implant-Based Reconstruction

Implant-based reconstruction uses silicone implants, placed either above or beneath the chest wall muscle (prepectoral or dual plane), to recreate the breast mound. In the risk-reducing setting where nipple-sparing mastectomy is used, implant-based reconstruction produces a very natural-appearing result with the nipple preserved in its natural position.

Direct-to-implant (DTI) reconstruction places a permanent silicone implant at the time of mastectomy in a single stage. It is suitable for women with smaller to medium breasts and a good skin envelope, and avoids the need for a tissue expander phase. Modern prepectoral DTI reconstruction using biological mesh (ADM) or synthetic mesh support produces excellent results and a faster, more comfortable recovery than submuscular approaches.

Two-stage expander-implant reconstruction uses a tissue expander at the time of mastectomy, gradually inflated over several weeks before exchange to a permanent implant in a second procedure. This approach is used when direct-to-implant reconstruction is not safe due to the quality or quantity of skin available, or when a larger implant is required that needs more tissue expansion to accommodate.

Fat transfer (lipofilling) is commonly used as a refinement adjunct after implant reconstruction — to improve contour, smooth irregularities, and improve the softness and natural feel of the reconstructed breast. It is performed as a day procedure and can be repeated as needed.

Autologous (Own Tissue) Reconstruction

For women who prefer a reconstruction made from their own tissue, autologous reconstruction is available using tissue from the abdomen (DIEP flap or TRAM flap) or the back (latissimus dorsi flap). Autologous reconstruction produces a reconstruction that feels and moves naturally, ages with the body, and does not involve implants.

In the risk-reducing setting, where post-mastectomy radiotherapy is not required, implant-based reconstruction is more commonly chosen than autologous reconstruction due to its shorter operative time and recovery. However, autologous reconstruction remains an excellent and valid option, particularly for women who prefer it or who are not suitable for implants.

A full discussion of reconstruction options — including the advantages, trade-offs, and what is realistic for your anatomy — takes place at your pre-operative consultation. We encourage patients to take as much time as they need with this decision and to attend multiple consultations if helpful.

Choosing Not to Have Reconstruction

Some women choose to have risk-reducing mastectomy without reconstruction, opting for a flat chest wall closure (Aesthetic Flat Closure). This is a completely valid and supported choice. Bilateral flat closure is a chest wall reconstruction that some women actively prefer, and our team provides equal support and the same standard of surgical care regardless of the reconstruction decision.

External prostheses worn in a bra can provide an excellent and comfortable alternative to reconstruction for women who choose a flat closure, and our team will facilitate referral to a prosthesis fitting service. Some women, on the other hand, prefer to “go flat” and embrace their decision.

What Risk-Reducing Mastectomy Does and Does Not Achieve

Risk-reducing bilateral mastectomy reduces the lifetime risk of breast cancer by approximately 95%. It is the most effective single intervention available for reducing breast cancer risk in gene carriers. For many women, particularly those who have seen close family members affected by breast cancer, the reduction in risk and the relief from ongoing anxiety about developing the disease can be profoundly transformative.

It is important to understand that risk-reducing mastectomy does not eliminate breast cancer risk entirely. A small amount of breast tissue always remains after mastectomy, even with the most thorough surgical technique, and this residual tissue retains a small residual risk. The lifetime risk after risk-reducing mastectomy is estimated at around 1 to 5% depending on the mutation, compared to 50 to 72% without surgery.

Risk-reducing mastectomy does not reduce the risk of ovarian cancer. For BRCA1 and BRCA2 carriers, ovarian cancer risk is a separate and important consideration that is managed through risk-reducing salpingo-oophorectomy (surgical removal of the fallopian tubes and ovaries), typically recommended from age 35 to 40 for BRCA1 carriers and somewhat later for BRCA2. The decision about ovarian surgery is closely related to but separate from the breast surgery decision, and both are discussed as part of a comprehensive risk management plan.

Risk-Reducing Mastectomy and Fertility

For premenopausal women of reproductive age who have not yet completed their family, the question of future fertility is an important consideration in the timing of risk-reducing surgery.

Risk-reducing mastectomy itself has no direct effect on fertility. However, the related question of risk-reducing ovarian surgery — which does cause permanent infertility if performed before menopause — is closely linked and requires careful consideration of family-building plans.

For women who are considering risk-reducing mastectomy and wish to preserve fertility for the future, there is generally no urgency that would require surgery before family-building plans are completed, provided appropriate breast surveillance is maintained in the interim. Your surgeon will discuss the timing considerations openly and without pressure.

Emotional Dimensions of Risk-Reducing Surgery

Choosing to remove healthy breasts in order to prevent a disease you do not yet have is a decision that sits outside the ordinary experience of medical care. It involves genuine grief — for breasts, for a body that feels changed, for the loss of the choice itself. Even women who feel entirely certain about their decision often find the experience of surgery and recovery more emotionally complex than they anticipated.

This emotional dimension is normal, valid, and deserves acknowledgment and support. The experience of having a high-risk gene mutation — and the surveillance, uncertainty, decision-making, and family implications that come with it — carries a cumulative psychological weight that should not be underestimated.

Our practice is committed to supporting patients through this experience with more than just surgical expertise. Your breast care nurse is involved throughout the process. Psychological support and counselling are actively available. And we encourage patients to connect with peer support — speaking with women who have been through risk-reducing mastectomy firsthand is consistently described as one of the most valuable things a patient can do in preparing for surgery. Breast Cancer Network Australia (BCNA) coordinates peer support that can match you with a trained volunteer who has been through a similar experience. Inherited Cancers Australia is a not for profit organisation for people with familial genetic mutations and offers information, support groups and contact with other people who have had similar experiences.

Recovery After Risk-Reducing Mastectomy with Reconstruction

Recovery varies depending on the type of reconstruction performed, and is similar to that described for mastectomy and reconstruction in those respective pages. In general, bilateral mastectomy with implant-based reconstruction requires a hospital stay of two to three nights, with most patients managing light activities within two weeks and returning to full activity by six to eight weeks. Bilateral autologous reconstruction involves a longer hospital stay and recovery reflecting the more extensive nature of the donor site surgery.

Your breast care nurse will support you through the recovery process with practical information, emotional check-ins, and coordination of follow-up care.

Follow-Up After Risk-Reducing Mastectomy

Following risk-reducing mastectomy, ongoing follow-up is recommended to monitor the reconstruction and assess the small residual breast tissue that remains. Clinical review is typically arranged at six weeks, three months, six months, and annually thereafter.

Breast imaging after risk-reducing mastectomy is not routinely required in the same way as before surgery, as the vast majority of breast tissue has been removed. Your surgeon and geneticist will advise on any ongoing surveillance requirements based on your individual circumstances and residual risk.

Risk-Reducing Surgery at Breast & Surgical Oncology at The Poche Centre

Our surgeons have extensive experience in risk-reducing mastectomy and reconstruction for high-risk gene carriers. We understand the unique clinical and emotional context of this surgery and approach every consultation with the care, honesty, and patience it requires.

We work closely with familial cancer services, clinical geneticists, medical oncologists, and fertility specialists to ensure every patient is comprehensively supported across all dimensions of their risk management. We are equally supportive of patients who choose surveillance over surgery, and we will never pressure a decision in either direction.

If you carry a high-risk gene mutation and would like to discuss your surgical options, or if you have been referred to us for a risk management consultation, we welcome the opportunity to meet with you.

This page is intended as a general guide only and does not replace personalised medical advice. Risk-reducing surgery decisions are highly individual and should always be made in the context of formal genetic counselling and specialist surgical assessment.